Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global Duchenne Muscular Dystrophy Drugs Market by Product Type, Therapeutic Approach, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.
The global Duchenne muscular dystrophy (DMD) drugs market is currently experiencing a significant growth period, with projections indicating a climb from US$ 2.3 Billion in 2023 to an impressive US$ 5.5 Billion by the year 2032. This growth is anticipated to occur at a compound annual growth rate (CAGR) of 10.17% over the forecast period, driven by the increasing prevalence of DMD, a range of new product approvals, launches, and a favorable landscape shaped by government initiatives and reimbursement policies conducive to target-specific treatments.
A notable trend positively influencing the global market is the surge in new product approvals and launches, which correlates with the rising cases of DMD. Moreover, advancements such as mutation-specific therapies and innovation in diagnostics are pushing the industry forward. Continuous research and development aimed at optimizing treatment for under-represented patient groups like infants and females, are further inclining market trajectories upward.
However, challenges such as delayed diagnoses, cost concerns of genetic therapeutics, and the lack of standardized procedures for the assessment of the clinical efficacy of drugs present hurdles to the market's expansion. Nevertheless, government initiatives and improved medical infrastructure, particularly in urban areas, coupled with increasing disposable incomes, are expected to create numerous growth opportunities in the Duchenne muscular dystrophy drugs sector.
Market Segmentation and Analysis
The comprehensive analysis within the global DMD drugs market delves into segments based on product types, with corticosteroids holding a significant share. Other product types like prednisolone, prednisone, and deflazacort, along with pain management drugs, are among those covered. Therapeutic approaches such as mutation suppression, exon skipping, and steroid therapy are examined, with exon skipping therapy being notably prevalent.
Furthermore, the market research covers end-user segmentation, which includes hospitals, clinics, and home care settings, with hospitals emerging as the dominant end-user sector. Regional insights into key markets, including North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa, are also provided, with North America leading the global market.
Competitive Landscape and Key Players
The report sheds light on the competitive environment of the Duchenne muscular dystrophy drugs market, showcasing the strategies and analytics of leading players. With a focus on the synthesis of innovation, business growth, and market strategy, the analysis provides visibility into the dominant actors shaping the industry landscape.
In conclusion, this insightful review of the Duchenne muscular dystrophy drugs market foreshadows significant growth through 2032, bolstered by technological advancements, strategic industry activities, and support from governmental bodies across the globe. The comprehensive analysis offers valuable insights for stakeholders and participants navigating this evolving market space.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 136 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value (USD) in 2023 | $2.3 Billion |
| Forecasted Market Value (USD) by 2032 | $5.5 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
Companies Featured
- FibroGen Inc.
- Italfarmaco S.p.A.
- NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals
- Sarepta Therapeutics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/insvnl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
